- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy ; volume:269 ; number:1 ; day:8 ; month:12 ; year:2021 ; pages:534-536 ; date:1.2022
Journal of neurology ; 269, Heft 1 (8.12.2021), 534-536, 1.2022
- Creator
-
Talaei, M.
Robertson, N. P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-021-10908-9
- URN
-
urn:nbn:de:101:1-2022042407335524653382
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Talaei, M.
- Robertson, N. P.
- SpringerLink (Online service)
Other Objects (12)
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy
IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy
IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy
IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy